Tag: 3BL

Duke Energy coordinates with local chambers to distribute fundsGrants to support minority-, women-, or veteran-owned small businesses

CINCINNATI, December 7, 2023 /3BL/ – November 25th was Small Business Saturday, a day dedicated to celebrating and supporting small businesses that keep communities vibrant. The Duke Energy Foundation has partnered with six local chambers of commerce and the Miami University Small Business Office to award $275,000 in grants to more than 60 local small businesses.

Under this partnership, the Duke Energy Foundation supplies the funding, while the chambers and Miami University Small Business Office determine the businesses to which the funds are granted. Preference is given to minority-, women- and veteran-owned businesses. Funds may be used for a broad array of expenditures including but not limited to physical space adaptability and beautification, technology improvements, talent sourcing, job posting fees, and professional development training costs.

“With the holidays upon us, our local small businesses are working tirelessly to serve their customers,” said Amy Spiller, president, Duke Energy Ohio and Kentucky. “We hope these funds bring a little extra cheer to those business owners who continue to navigate the current economy. And, as always, we encourage everyone to shop small.”

The Small Business Assistance grant program was first developed in 2020 to help small businesses survive and rebound from the pandemic. Since then, the Duke Energy Foundation has partnered with local chambers to provide approximately $880,000 in assistance to small businesses.

“Duke Energy continues to be an important partner to the Cincinnati Regional Chamber, and a great neighbor to our region’s small business community,” said Brendon Cull, president and CEO of the Cincinnati Chamber. “We hope these small business owners understand how critically important they are to our local economy and feel supported this season.”

The following small businesses have been selected to receive this year’s Duke Energy Foundation Small Business Assistance Grants:

Brown County Chamber of Commerce ($25,000)

Bushel N A Peck LLCCurry’s Crafting CornerHometown Screen PrintingJail Break InnLu Lu’s SudsNational Alliance of Mental Illness (NAMI) Brown CountyR. Varney Photography & MarketingR&R Poultry FarmRedeemed Homestead

Cincinnati USA Regional Chamber ($75,000)

Blossoms Florist IncBonus GolfCream + Sugar CoffeehouseDEFINE OakleyDJX Construction Company LLCKOFINAS OLIVE OILLentz & CompanyLoVe on FourthMad Cheese, LLCMinks By Marie LLCOlive Tree Catering LLCOTR FunplexRushFit StudioSweet Sistah Splash – Sheba MamaWaverly’s Hope Child Care LLC

Clermont Chamber of Commerce ($25,000)

Back the Hero RumbleClear Mountain Food ParkDebi’s Cut & CurlDigiMax Graphics PlusTano Bistro & Catering

Grant County Chamber of Commerce ($25,000)

Beauty & the BeardBody Works GymBrowning’s Country HamThe Colonel’s CreameryCornerstone EquipmentDry Ridge AutoElla Mae’s SundaesFarmhouse FurnitureMinuteman PressIvy Leaf FloristJim Simpson Realtors, IncMy Kiddie CollegeSaylor Trailer Sales, LLCShirt & Stuff Happens LLC

Miami University Small Business Office – Butler County ($25,000)

Central StudioThe Cracked PotDot’s Beauty SalonJessica Hyath PhotographyNail IDSmooth Music GroupSantosha StudioTailor Made Counseling Services

Northern Kentucky Chamber of Commerce ($75,000)

Airtrek RoboticsBailey Ross LLC dba Thrive Empowerment CenterClear Mountain Food ParkColonel De Gourmet Herbs & SpicesDebi’s Cut & CurlGolden Gelato CompanyInspired FashionKealoha’s KitchenTwin Bistro & Catering dba The GruffUnion Music AcademyUnique International Market

Warren County Foundation ($25,000)

To be announced in early December

Duke Energy Foundation

The Duke Energy Foundation provides more than $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.

Duke Energy Ohio and Kentucky

Duke Energy Ohio/Kentucky, a subsidiary of Duke Energy, provides electric service to 900,000 residential, commercial and industrial customers in a 3,000-square-mile service area, and natural gas service to 550,000 customers in a 2,650-square-mile service area, in Ohio and Kentucky.

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America’s largest energy holding companies. Its electric utilities serve 8.2 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 50,000 megawatts of energy capacity. Its natural gas unit serves 1.6 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The company employs 27,600 people.

Duke Energy is executing an aggressive clean energy transition to achieve its goals of net-zero methane emissions from its natural gas business by 2030 and net-zero carbon emissions from electricity generation by 2050. The company has interim carbon emission targets of at least 50% reduction from electric generation by 2030, 50% for Scope 2 and certain Scope 3 upstream and downstream emissions by 2035, and 80% from electric generation by 2040. In addition, the company is investing in major electric grid enhancements and energy storage, and exploring zero-emission power generation technologies such as hydrogen and advanced nuclear.

Duke Energy was named to Fortune’s 2023 “World’s Most Admired Companies” list and Forbes’ “World’s Best Employers” list. More information is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos and videos. Duke Energy’s illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.

Media contact: Casey Kroger Media line: 800.559.3853 Twitter: @DE_CaseyK

View original content here.

Duke Energy coordinates with local chambers to distribute fundsGrants to support minority-, women-, or veteran-owned small businesses

CINCINNATI, December 7, 2023 /3BL/ – November 25th was Small Business Saturday, a day dedicated to celebrating and supporting small businesses that keep communities vibrant. The Duke Energy Foundation has partnered with six local chambers of commerce and the Miami University Small Business Office to award $275,000 in grants to more than 60 local small businesses.

Under this partnership, the Duke Energy Foundation supplies the funding, while the chambers and Miami University Small Business Office determine the businesses to which the funds are granted. Preference is given to minority-, women- and veteran-owned businesses. Funds may be used for a broad array of expenditures including but not limited to physical space adaptability and beautification, technology improvements, talent sourcing, job posting fees, and professional development training costs.

“With the holidays upon us, our local small businesses are working tirelessly to serve their customers,” said Amy Spiller, president, Duke Energy Ohio and Kentucky. “We hope these funds bring a little extra cheer to those business owners who continue to navigate the current economy. And, as always, we encourage everyone to shop small.”

The Small Business Assistance grant program was first developed in 2020 to help small businesses survive and rebound from the pandemic. Since then, the Duke Energy Foundation has partnered with local chambers to provide approximately $880,000 in assistance to small businesses.

“Duke Energy continues to be an important partner to the Cincinnati Regional Chamber, and a great neighbor to our region’s small business community,” said Brendon Cull, president and CEO of the Cincinnati Chamber. “We hope these small business owners understand how critically important they are to our local economy and feel supported this season.”

The following small businesses have been selected to receive this year’s Duke Energy Foundation Small Business Assistance Grants:

Brown County Chamber of Commerce ($25,000)

Bushel N A Peck LLCCurry’s Crafting CornerHometown Screen PrintingJail Break InnLu Lu’s SudsNational Alliance of Mental Illness (NAMI) Brown CountyR. Varney Photography & MarketingR&R Poultry FarmRedeemed Homestead

Cincinnati USA Regional Chamber ($75,000)

Blossoms Florist IncBonus GolfCream + Sugar CoffeehouseDEFINE OakleyDJX Construction Company LLCKOFINAS OLIVE OILLentz & CompanyLoVe on FourthMad Cheese, LLCMinks By Marie LLCOlive Tree Catering LLCOTR FunplexRushFit StudioSweet Sistah Splash – Sheba MamaWaverly’s Hope Child Care LLC

Clermont Chamber of Commerce ($25,000)

Back the Hero RumbleClear Mountain Food ParkDebi’s Cut & CurlDigiMax Graphics PlusTano Bistro & Catering

Grant County Chamber of Commerce ($25,000)

Beauty & the BeardBody Works GymBrowning’s Country HamThe Colonel’s CreameryCornerstone EquipmentDry Ridge AutoElla Mae’s SundaesFarmhouse FurnitureMinuteman PressIvy Leaf FloristJim Simpson Realtors, IncMy Kiddie CollegeSaylor Trailer Sales, LLCShirt & Stuff Happens LLC

Miami University Small Business Office – Butler County ($25,000)

Central StudioThe Cracked PotDot’s Beauty SalonJessica Hyath PhotographyNail IDSmooth Music GroupSantosha StudioTailor Made Counseling Services

Northern Kentucky Chamber of Commerce ($75,000)

Airtrek RoboticsBailey Ross LLC dba Thrive Empowerment CenterClear Mountain Food ParkColonel De Gourmet Herbs & SpicesDebi’s Cut & CurlGolden Gelato CompanyInspired FashionKealoha’s KitchenTwin Bistro & Catering dba The GruffUnion Music AcademyUnique International Market

Warren County Foundation ($25,000)

To be announced in early December

Duke Energy Foundation

The Duke Energy Foundation provides more than $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.

Duke Energy Ohio and Kentucky

Duke Energy Ohio/Kentucky, a subsidiary of Duke Energy, provides electric service to 900,000 residential, commercial and industrial customers in a 3,000-square-mile service area, and natural gas service to 550,000 customers in a 2,650-square-mile service area, in Ohio and Kentucky.

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America’s largest energy holding companies. Its electric utilities serve 8.2 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 50,000 megawatts of energy capacity. Its natural gas unit serves 1.6 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The company employs 27,600 people.

Duke Energy is executing an aggressive clean energy transition to achieve its goals of net-zero methane emissions from its natural gas business by 2030 and net-zero carbon emissions from electricity generation by 2050. The company has interim carbon emission targets of at least 50% reduction from electric generation by 2030, 50% for Scope 2 and certain Scope 3 upstream and downstream emissions by 2035, and 80% from electric generation by 2040. In addition, the company is investing in major electric grid enhancements and energy storage, and exploring zero-emission power generation technologies such as hydrogen and advanced nuclear.

Duke Energy was named to Fortune’s 2023 “World’s Most Admired Companies” list and Forbes’ “World’s Best Employers” list. More information is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos and videos. Duke Energy’s illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.

Media contact: Casey Kroger Media line: 800.559.3853 Twitter: @DE_CaseyK

View original content here.

SANTA CLARA, Calif., December 7, 2023 /3BL/ – Applied Materials, Inc. announced that its science-based Scope 1, 2 and 3 emissions reduction targets have received validation from the Science Based Targets initiative (SBTi). By setting a 1.5°C-aligned target, currently the most ambitious designation available through the SBTi process, Applied is aligning its emissions reduction program to the latest climate science, validated by a third party, and will report its progress annually.

“Semiconductors are the foundation of technology advancements that are transforming the global economy and can improve peoples’ lives in so many ways. As demand for semiconductors increases, we must grow responsibly by collaborating broadly to reduce the industry’s environmental impact,” said Gary Dickerson, President and CEO of Applied Materials. “SBTi’s validation of our emissions reduction targets reflects Applied Materials’ commitment to minimize our own carbon footprint and to work closely with our suppliers and customers to help them achieve their climate goals.”

Applied’s Scope 1 and Scope 2 greenhouse gas emissions are those produced directly by the company and by the energy it purchases. Its Scope 3 emissions, which make up more than 99 percent of Applied’s carbon footprint, consist of the upstream emissions from the company’s supply chain and the downstream emissions from the use of its products by customers. Following are Applied’s near-term science-based targets that have received SBTi validation:

Applied Materials, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 50% by FY2030 from a FY2019 base year.Applied Materials, Inc. also commits to increase active annual sourcing of renewable electricity from 36% in FY2019 to 100% by FY2030.Applied Materials, Inc. further commits to reduce scope 3 GHG emissions from use of sold products 55% per million USD of value added by FY2030 from a FY2019 base year.

In order to achieve its ambitious emissions reduction targets, particularly Scope 3, Applied will collaborate closely with its customers, suppliers and industry partners, as outlined in the company’s Net Zero 2040 Playbook unveiled earlier this year. Areas of focus include:

Furthering Applied’s “3×30” program, which defines goals for improving the energy efficiency and reducing the chemical impacts of its semiconductor manufacturing equipmentEngaging and supporting customers to transition to clean energy to power their chip manufacturing facilities where Applied’s equipment is usedSupporting grid decarbonization efforts in key markets through advocacy and industry initiatives

In July, Applied joined with Intel as the inaugural corporate sponsors of Schneider Electric’s Catalyze program, which aims to accelerate access to renewable energy across the global semiconductor value chain. Applied is also a founder and Governing Council member of the Semiconductor Climate Consortium, a global, ecosystem-wide effort to accelerate the semiconductor industry’s greenhouse gas-reduction efforts.

Applied Materials has been reporting on social responsibility and environmental matters since 2005. The company’s latest Sustainability Report and Annex reflect activities and results through the end of fiscal year 2022. To access the full reports and learn more about Applied’s environmental actions as well as the company’s efforts to advance its culture of inclusion and human rights initiatives, please visit the Reports and Policies page of our website.

Forward-Looking Statements and Reporting Uncertainties 
This release contains forward-looking statements, including our sustainability strategies and targets and other statements that are not historical facts. These statements, and their underlying assumptions and projections, are subject to risks and uncertainties, and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: our and the industry’s ability to achieve sustainability strategies and goals; failure to realize the anticipated benefits of planned investments and technology innovations related to sustainability; the level of demand for semiconductors and our products; customers’ technology and capacity requirements; the introduction of new and innovative technologies, and the timing of technology transitions; our ability to develop, deliver and support new products and technologies; market acceptance of existing and newly developed products; and other risks and uncertainties included in the “Risk Factors” section of our SEC filings, including our recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and we assume no obligation to update them.

Non-financial information is subject to measurement uncertainties resulting from limitations inherent in the nature and methods used for determining such data. The selection of different but acceptable measurement techniques can result in materially different measurements.

About Applied Materials 
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible a better future. Learn more at www.appliedmaterials.com.

Contact: 
Ricky Gradwohl (editorial/media) 408.235.4676 
Michael Sullivan (financial community) 408.986.7977

SANTA CLARA, Calif., December 7, 2023 /3BL/ – Applied Materials, Inc. announced that its science-based Scope 1, 2 and 3 emissions reduction targets have received validation from the Science Based Targets initiative (SBTi). By setting a 1.5°C-aligned target, currently the most ambitious designation available through the SBTi process, Applied is aligning its emissions reduction program to the latest climate science, validated by a third party, and will report its progress annually.

“Semiconductors are the foundation of technology advancements that are transforming the global economy and can improve peoples’ lives in so many ways. As demand for semiconductors increases, we must grow responsibly by collaborating broadly to reduce the industry’s environmental impact,” said Gary Dickerson, President and CEO of Applied Materials. “SBTi’s validation of our emissions reduction targets reflects Applied Materials’ commitment to minimize our own carbon footprint and to work closely with our suppliers and customers to help them achieve their climate goals.”

Applied’s Scope 1 and Scope 2 greenhouse gas emissions are those produced directly by the company and by the energy it purchases. Its Scope 3 emissions, which make up more than 99 percent of Applied’s carbon footprint, consist of the upstream emissions from the company’s supply chain and the downstream emissions from the use of its products by customers. Following are Applied’s near-term science-based targets that have received SBTi validation:

Applied Materials, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 50% by FY2030 from a FY2019 base year.Applied Materials, Inc. also commits to increase active annual sourcing of renewable electricity from 36% in FY2019 to 100% by FY2030.Applied Materials, Inc. further commits to reduce scope 3 GHG emissions from use of sold products 55% per million USD of value added by FY2030 from a FY2019 base year.

In order to achieve its ambitious emissions reduction targets, particularly Scope 3, Applied will collaborate closely with its customers, suppliers and industry partners, as outlined in the company’s Net Zero 2040 Playbook unveiled earlier this year. Areas of focus include:

Furthering Applied’s “3×30” program, which defines goals for improving the energy efficiency and reducing the chemical impacts of its semiconductor manufacturing equipmentEngaging and supporting customers to transition to clean energy to power their chip manufacturing facilities where Applied’s equipment is usedSupporting grid decarbonization efforts in key markets through advocacy and industry initiatives

In July, Applied joined with Intel as the inaugural corporate sponsors of Schneider Electric’s Catalyze program, which aims to accelerate access to renewable energy across the global semiconductor value chain. Applied is also a founder and Governing Council member of the Semiconductor Climate Consortium, a global, ecosystem-wide effort to accelerate the semiconductor industry’s greenhouse gas-reduction efforts.

Applied Materials has been reporting on social responsibility and environmental matters since 2005. The company’s latest Sustainability Report and Annex reflect activities and results through the end of fiscal year 2022. To access the full reports and learn more about Applied’s environmental actions as well as the company’s efforts to advance its culture of inclusion and human rights initiatives, please visit the Reports and Policies page of our website.

Forward-Looking Statements and Reporting Uncertainties 
This release contains forward-looking statements, including our sustainability strategies and targets and other statements that are not historical facts. These statements, and their underlying assumptions and projections, are subject to risks and uncertainties, and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: our and the industry’s ability to achieve sustainability strategies and goals; failure to realize the anticipated benefits of planned investments and technology innovations related to sustainability; the level of demand for semiconductors and our products; customers’ technology and capacity requirements; the introduction of new and innovative technologies, and the timing of technology transitions; our ability to develop, deliver and support new products and technologies; market acceptance of existing and newly developed products; and other risks and uncertainties included in the “Risk Factors” section of our SEC filings, including our recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and we assume no obligation to update them.

Non-financial information is subject to measurement uncertainties resulting from limitations inherent in the nature and methods used for determining such data. The selection of different but acceptable measurement techniques can result in materially different measurements.

About Applied Materials 
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible a better future. Learn more at www.appliedmaterials.com.

Contact: 
Ricky Gradwohl (editorial/media) 408.235.4676 
Michael Sullivan (financial community) 408.986.7977

HAMILTON, Bermuda, December 7, 2023 /3BL/ – Family-owned spirits company, Bacardi has successfully completed the world’s first commercial production of a glass spirits bottle fueled by hydrogen in a trial that took place earlier this month.

Bacardi worked with premium glassmaker, Hrastnik1860, to pioneer new technology that powered a glass furnace with hydrogen as its primary energy source and in doing so cut the Greenhouse Gas (GHG) emissions typically produced as a byproduct of glass bottle production.

The bottle, which for the purposes of the trial was the iconic ST-GERMAIN® elderflower liqueur bottle, is identical in appearance to the bottle produced using traditional methods and will reach bars and stores in the coming weeks.

Over the course of the trial, which produced 150,000 of the brand’s 70cl glass bottles, hydrogen contributed more than 60% of the fuel for the glass furnace, cutting GHG emissions by more than 30%.

“Piloting this lower carbon glass production is another example of Bacardi leading the industry in environmental best practice,” says Rodolfo Nervi, Vice President, Safety, Quality and Sustainability for Bacardi. “We will take the learnings from the trial to help shape a pathway to hydrogen-fueled glass production and create a blueprint for others to follow. It’s only through making change as an industry that we can bring significant change to our impact on the environment.”

Peter Čas, CEO, Hrastnik1860 added: “Successfully producing lower emission, premium glass bottles at a commercial scale, with absolutely no compromise on quality, has made all the hard work worthwhile. Like Bacardi, we are committed to developing new innovations that lower emissions while maintaining premium quality. This revolutionary technology proves the two can go hand in hand and we are now taking the first steps in bringing it to market.”

To achieve its ambition of becoming the most environmentally responsible global spirits company, Bacardi is continuously investing in new innovations and exploring opportunities to use pioneering new technology to help achieve its ultimate goal of Net Zero.

Find out more about Bacardi and its ESG – Environmental, Social & Governance – commitments, including its alignment with the United Nations Sustainable Development Goals, at www.bacardilimited.com/good-spirited.

ENDS

For more information contact: 
Andrew Carney, Communications Director Europe, Bacardi – acarney@bacardi.com 
Jessica Merz, V.P. Global Corporate Communications, Bacardi – jmerz@bacardi.com

Always drink responsibly.

About Bacardi Limited

Bacardi Limited, the largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 161 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 9,000, operates production facilities in 11 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on LinkedIn, Instagram or X.

About Hrastnik1860

Hrastnik1860, a member of the Vaider Group, has more than 160 years of expertise in glass and is a global partner in the development and manufacturing of world-class engineered glass products. The company is known for creating technically demanding bottles, primarily for the spirits industry, and is a full-service solution partner—from R&D and consulting to innovative design, prototyping, manufacturing, decoration, and delivery. Hrastnik1860’s products are acclaimed for their perfect crystal shine and are entirely free of heavy metals. They range from traditional designs to innovative solutions that have won many prestigious awards. Visit www.hrastnik1860.com.

FOSTER CITY, Calif., December 6, 2023 /3BL/ – Gilead Sciences, Inc. (Nasdaq: GILD) announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.

Data featured in eight presentations include an analysis of clinical outcomes by age from the Phase 3 TROPiCS-02 study of Trodelvy in HR+/HER2- mBC, as well as a qualitative analysis of the experiences and perspectives of patients, caregivers and clinicians on clinical meaningfulness in mBC treatment decision-making. The study adds to a needed body of research exploring the importance of patient-centered interpretations of clinical meaningfulness (e.g., survival, quality of life).

“Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both second-line metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. “The data being presented at SABCS add to the breadth of evidence reinforcing Trodelvy’s use in these two difficult-to-treat breast cancers. Additionally, the real-world data being presented in metastatic breast cancer provide insights on quality of life and other measures of health to inform both providers and patients in making treatment decisions.”

Table of Accepted Abstracts (all times CDT):

Abstract DispositionAbstract Title

Poster # PO1-05-09

Wednesday, Dec. 6 12:00 PM

ASCENT-07: A Phase 3, Randomized, Open-Label Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post-Endocrine Therapy

Poster # PO1-06-10

Wednesday, Dec. 6 12:00 PM

Overall Survival Results From EVER-132-001, a Phase 2B Single-Arm Study of Sacituzumab Govitecan in Chinese Patients with Metastatic Triple-Negative Breast Cancer

Poster # PO1-04-06

Wednesday, Dec. 6 12:00 PM

Exposure-response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients with Metastatic Breast Cancer

Poster # PO1-06-08

Wednesday, Dec. 6 12:00 PM

Treatment Utilization by Race and Insurance Type Among TNBC Patients

Poster # PO1-10-06

Wednesday, Dec. 6 12:00 PM

Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making: Experiences and Perspectives of Patients, Caregivers, and Clinicians

Poster # PO2-05-03

Wednesday, Dec. 6 5:00 PM

Costs Associated with Adverse Events in Patients Receiving Treatment for Hormone Receptor Positive/Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer

Poster # PO2-05-02

Wednesday, Dec. 6 5:00 PM

Real-World Experience of Patients Receiving Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer: A Global Analysis of Symptoms and Side Effects

Poster # PO5-21-09

Friday, Dec. 8 12:00 PM

Clinical Outcomes by Age Subgroups in the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in HR+/HER2‒ Metastatic Breast Cancer

Trodelvy is recommended as a category 1 preferred treatment for second-line mTNBC and a category 1 preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network® (NCCN®) as defined in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®).1

About Trodelvy

Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.

Trodelvy is approved in almost 50 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Trodelvy is also approved in the U.S., the European Union, and multiple other global markets to treat certain patients with pre-treated HR+/HER2- metastatic breast cancer. In the U.S., Trodelvy also has accelerated approval for treatment of certain patients with second-line metastatic urothelial cancer (UC); see below for the full U.S. indication for Trodelvy.

Trodelvy is also being developed for potential investigational use in other TNBC, HR+/HER2- and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer.

U.S. Indications for Trodelvy

In the United States, Trodelvy is indicated for the treatment of adult patients with:

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.Locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

U.S. Important Safety Information for Trodelvy

BOXED WARNING: NEUTROPENIA AND DIARRHEA

Severe or life-threatening neutropenia may occur. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis. Initiate anti-infective treatment in patients with febrile neutropenia without delay.Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold Trodelvy until resolved to ≤Grade 1 and reduce subsequent doses.

CONTRAINDICATIONS

Severe hypersensitivity reaction to Trodelvy.

WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 64% of patients treated with Trodelvy. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold Trodelvy for neutropenic fever. Administer G-CSF as clinically indicated or indicated in Table 1 of USPI.

Diarrhea: Diarrhea occurred in 64% of all patients treated with Trodelvy. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with Trodelvy. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of Trodelvy was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue Trodelvy for Grade 4 infusion-related reactions.

Nausea and Vomiting: Nausea occurred in 64% of all patients treated with Trodelvy and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with Trodelvy. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, Trodelvy can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Trodelvy contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Trodelvy and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Trodelvy and for 3 months after the last dose.

ADVERSE REACTIONS

In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).

In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.

In the TROPHY study (locally advanced or metastatic urothelial cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, any infection, alopecia, decreased appetite, constipation, vomiting, rash, and abdominal pain. The most frequent serious adverse reactions (SAR) (≥5%) were infection (18%), neutropenia (12%, including febrile neutropenia in 10%), acute kidney injury (6%), urinary tract infection (6%), and sepsis or bacteremia (5%). SAR were reported in 44% of patients, and 10% discontinued due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPHY study were reduced neutrophils, leukocytes, and lymphocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of Trodelvy with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with Trodelvy.

UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with Trodelvy.

Please see full Prescribing Information, including BOXED WARNING.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical studies, including those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including with respect pending or potential applications for the treatment of metastatic TNBC, HR+/HER2- metastatic breast cancer, metastatic UC, metastatic NSCLC, metastatic SCLC, head and neck cancer, and endometrial cancer, in the currently anticipated timelines or at all; Gilead’s ability to receive regulatory approvals for such indications in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaim any intent to update any such forward-looking statements.

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

1 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Originally published by Gilead Sciences

December 6, 2023 /3BL/ – Ceres applauds U.S. Sens. Bill Cassidy (R – LA) and Sheldon Whitehouse (D – RI) for each introducing legislation that would create a Carbon Border Adjustment Mechanism (CBAM) — otherwise known as a foreign polluter fee — in the U.S. Together, the bills showcase a bipartisan opportunity to lower global climate pollution by leveraging American leadership in clean manufacturing, while also advancing U.S. economic, geopolitical, and national security interests.

The legislation from Sen. Cassidy and Sen. Whitehouse differ in some areas, but both bills are premised on assessing fees on imports that do not meet U.S. environmental standards, supporting domestic economic growth, and encouraging cleaner manufacturing overseas, including through export of U.S. technology.

“A carbon border adjustment mechanism would bring substantial climate, manufacturing, national security, and geopolitical benefits to the U.S. and its economy, while cementing America’s global leadership in clean industry and environmental stewardship,” said Zach Friedman, director of federal policy, Ceres. “This pro-growth, market-based policy has the support of U.S. companies and will encourage businesses and governments around the world to cut pollution that harms the climate and risks economic growth. It also presents a major opportunity to continue the boom in clean technology investment, bringing new economic opportunities across the U.S. while reducing pollution in the communities suffering the most from environmental damage both domestically and around the world. We are grateful to Sens. Cassidy and Whitehouse for introducing these bills, demonstrating the potential for U.S. trade policy that refuses to give polluters an unfair advantage. We urge lawmakers of both parties to negotiate a bipartisan bill to pass this Congress, giving America’s businesses and workers a level playing field to compete and win the race to build an abundant clean energy future for all.”

Throughout 2023, Ceres has worked to build support among companies and investors for a CBAM. In May, at the annual LEAD on a Clean Economy advocacy event, Ceres hosted Sen. Cassidy in a meeting with large U.S. companies to discuss the concept, and the organization has also supported efforts to quantify the pollution associated with foreign-made products and how it compares to U.S. products.

A CBAM would be especially valuable for the U.S. as other governments, including the European Union, introduce their own, setting up the possibility of trade agreements between markets that assess imports for their climate impacts. By leveraging recent federal legislation driving business investment in clean U.S. industry, it would also help to restore manufacturing in U.S. communities, while encouraging pollution reduction and clean energy investment in places most heavily impacted by pollution — both domestically and around the world.

About Ceres

Ceres is a nonprofit organization working with the most influential capital market leaders to solve the world’s greatest sustainability challenges. Through our powerful networks and global collaborations of investors, companies and nonprofits, we drive action and inspire equitable market-based and policy solutions throughout the economy to build a just and sustainable future. For more information, visit ceres.org and follow @CeresNews.

Media Contact: Helen Booth-Tobin, booth-tobin@ceres.org, 617-247-0700 ext. 214

Research shows that investing in women’s education and leadership development positively impacts communities at every level.

To realize this leadership potential, however, some women need a little boost.

Minerva BC is dedicated to helping to close the leadership gender gap by advancing the leadership of self-identified women and girls. For over two decades, the non-profit based in Vancouver, BC has helped women across the province reach their goals through education, mentorship, and leadership training.

“We are committed to changing the face of leadership,” says Ashley Milbury, Youth Programs Manager at Minerva BC. “We work with women and girls to realize their core values and key strengths, helping them step into the fullest versions of themselves as leaders.”

Minerva BC puts this into practice through its Learning to Lead program, which for over two decades has provided self-identified girls in high school with the opportunity to increase their confidence and explore their leadership potential. The mentorship opportunities woven into the programs build a network for participants as they move throughout their academic and career journey.

“For a very long time, there’s been a pretty narrow idea of what it means to be a leader,” says Milbury. “We’re trying to expand that definition.”

Enbridge is committed to building vibrant and sustainable communities near our operations, and has supported Minerva BC since 2021. Our recent $10,000 Fueling Futures grant helped Minerva BC with program expansion and hosting a one-day, in person Learning to Lead workshop in Prince George.

“This funding came at a really pivotal time when we wanted to grow our impact in the north,” says Milbury. “There has been so much interest in this program, and we’re thrilled to be able to expand our offerings places such as Prince George.”

In addition to Learning to Lead, Minerva BC runs other skills and development programs like its Making Space for Youth Leadership program, which brings together women leaders from diverse backgrounds and different industries to engage in a two-way exchange of knowledge.

“Many of our mentors, regardless of whether they’ve been enrolled in our programs, are really inspired to offer something that their teenage selves would have benefited from,” say Milbury. “They want to help give that advice that they wish they had known at that time—just to help make that path a little bit smoother for the generation coming up.”

The ultimate goal is for participants to leave the program with greater self-awareness and the inspiration to take on new challenges and opportunities.

“The participants in our programs come here so ready to take on the world and tackle any challenges—and we get to create a space where they can start to tap in and uncover who they really are,” says Milbury.

“I feel lucky just to play a role in creating a space where their brilliance is going to emerge. It always does.”

Originally published on Dec 05, 2023 on Investors.Sysco.com

HOUSTON, December 6, 2023 /3BL/ – Sysco Corporation (NYSE:SYY), the leading global foodservice distribution company, announced today that its colleagues volunteered nearly 17,000 hours during its first ever global Purpose month in November 2023. This global event was a demonstration of the company’s purpose of Connecting the World to Share Food and Care for One Another.

Sysco colleagues participated in over 500 company-sponsored events or volunteered on their own across the United States, Canada, Sri Lanka, the U.K. and Ireland. More than 125 Sysco locations coordinated ways for colleagues to give back by packing meals that support hunger relief, packing amenity kits, hosting blood drives, or writing cards for military care packages.

“I’m so proud of what the Sysco team has achieved together; there’s no better way to celebrate International Volunteer Day than to show the power of collective effort to make a big difference,” said Neil Russell, Sysco’s Chief Administrative Officer. “This is an important time of year for food banks and other organizations as they gear up to support our community this holiday season, and together, we contributed significantly to Sysco’s Global Good Goal of donating $500 million worth of good by 2025.”

Sites with the highest participation rate and volunteer hours per colleague will receive a prize donation to make to a hunger-focused charity of their choice. To learn more about Sysco’s Volunteer Recognition Program and its Global Good Goal, see Sysco’s 2023 Sustainability Report.

About Sysco

Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 72,000 colleagues, the company operates 334 distribution facilities worldwide and serves approximately 725,000 customer locations. For fiscal year 2023 that ended July 1, 2023, the company generated sales of more than $76 billion. Information about our Sustainability program, including Sysco’s 2022 Sustainability Report and 2022 Diversity, Equity & Inclusion Report, can be found at www.sysco.com.

For more information, visit www.sysco.com or connect with Sysco on Facebook at www.facebook.com/SyscoFoods. For important news and information regarding Sysco, visit the Investor Relations section of the company’s Internet home page at investors.sysco.com, which Sysco plans to use as a primary channel for publishing key information to its investors, some of which may contain material and previously non-public information. In addition, investors should continue to review our news releases and filings with the SEC. It is possible that the information we disclose through any of these channels of distribution could be deemed to be material information.

For more information contact:

Media Contact 
Shannon Mutschler 
Mutschler.Shannon@sysco.com 
281-584-4059

View original content here.

By Candace Higginbotham

Giving Tuesday began as an idea to rally people together to do good for others on the Tuesday after Thanksgiving – following the big “shopping holidays” of Black Friday, Small Business Saturday and Cyber Monday.

And it’s clearly taken hold. 2022 was a record year for Giving Tuesday contributions globally, with $3.1 billion in giving last year – a 15% increase.

Serving our communities is at the heart of Regions’ business and associates serve in many ways – through volunteerism, board service and philanthropy.

Full-time Regions associates and recent retirees can put their financial gifts to work – on Giving Tuesday or any other day – using the company’s Matching Gift program. This benefit doubles eligible donations to nonprofit organizations with a one-to-one monetary matching gift up to $1,000 per year.

The most impactful match was when I was approached by a school that I support to seed a matching grant for one of their speed fund-raising events.

Linda Lockwood, an Institutional Trust relationship consultant in St. Louis, has taken advantage of the matching gift program for several years. She has used the matching funds for organizations such as local museums, the public library, her granddaughter’s schools and the Missouri Botanical Garden. Lockwood enjoys being able to use the program to give to her favorite causes at a higher level.

“The most impactful match was when I was approached by a school that I support to seed a matching grant for one of their speed fund-raising events,” Lockwood said. “So, with my donation doubled through Regions, they used my combined dollars as a match to another donor, which made the impact of my giving four times greater.”

Organizations that qualify for the Regions Matching Gift program must have a primary mission that fits into one of the following categories:

Economic and Community DevelopmentEducation and Workforce ReadinessFinancial WellnessArts and CultureService Members and VeteransIndividuals with Disabilities

“Our associates are extremely generous – with their time and their philanthropy,” said Gina Sian, Regions Community Affairs Execution and Operations manager. “Their generosity is making life better for our local communities year-round, and Giving Tuesday is a great reminder of the Matching Gifts program that Regions offers us to make the most of our contributions.”

Community service to me means giving back because you are blessed with the means to do it.

According to Durnita Cooperwood, a contact center manager based in Memphis, Tennessee, the Matching Gifts program allows her to put her personal convictions into action. “Community service to me means giving back because you are blessed with the means to do it,” Cooperwood said.

“With the Regions Matching Gift program, I am making a bigger impact on someone else’s life outside of my family and friends,” she continued. “I know the appreciation and the support goes a long way and it makes me feel I am not just talking about my passion, but I am doing something about it.”

Both Cooperwood and Lockwood recommend the program to all Regions associates. “If you are passionate about an organization, why wouldn’t you want to double the impact?” Lockwood says. “It is a really easy process.”